Novocure Ltd (OQ:NVCR)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
See Regulatory Filings on SEC
Company Contact
Address: Forum, NO. 4 Grenville Street
Tel: N/A
IR: See website
Key People
William F. Doyle
Executive Chairman of the Board
Asaf Danziger
President, Chief Executive Officer, Director
Wilhelmus Groenhuysen
Chief Financial Officer
Ely Benaim
Chief Medical Officer
Michael J. Ambrogi
Chief Operating Officer
Todd Longsworth
General Counsel
Pritesh Shah
Chief Commercial Officer
Business Overview
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.
Financial Overview
For the three months ended 31 March 2020, Novocure Ltd revenues increased 39% to $101.8M. Net loss before extraordinary items decreased 40% to $7.3M. Revenues reflect United States segment increase of 49% to $69.3M, Japan segment increase of 91% to $6.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.13 to -$0.07.
Employees: 782 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $6,591M as of Mar 31, 2020
Annual revenue (TTM): $379.84M as of Mar 31, 2020
EBITDA (TTM): $10.24M as of Mar 31, 2020
Net annual income (TTM): -$2.40M as of Mar 31, 2020
Free cash flow (TTM): $21.62M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 100,440,295 as of Apr 23, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization